Biocon Acquires Pfizer R&D Center In India

Biocon Biologics has acquired a biologics research facility in southern India from Pfizer that will employ 250 scientists and enable the company to pursue “breakthrough innovation.” 

Chennai
The Pfizer site is located in Chennai, India • Source: Shutterstock

Biocon has acquired a 60,000 square feet research and development site from Pfizer to “fast-forward” its biosimilars development. Subsidiary Biocon Biologics, set up in 2017 by Biocon as a separate subsidiary to house its biologics assets, described the “bench-to-pilot-scale” biologics research facility, located in the southern Indian city of Chennai, as “state-of-the-art.” The facility will house over 250 scientists who will have access to R&D labs equipped with over 500 high-end process and analytical instruments. 

“This investment will allow us to fast-forward development of our biosimilars from lab to pilot scale,” said Biocon Biologics chief...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business